• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comorbidity and the increased mortality after hospitalization for stroke: a population-based cohort study.
CONCLUSION: Comorbidity, notably cancer and advanced renal or liver disease, increased one-year mortality after stroke beyond the combined effects expected from either disease acting alone. This article is protected by copyright. All rights reserved. PMID: 29171148 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 23, 2017 Category: Hematology Authors: Corraini P, Szépligeti SK, Henderson VW, Ording AG, Horváth-Puhó E, Sørensen HT Tags: J Thromb Haemost Source Type: research

Comorbidity and the increased mortality after hospitalization for stroke: a population ‐based cohort study
ConclusionComorbidity, notably cancer and advanced renal or liver disease, increased one‐year mortality after stroke beyond the combined effects expected from either disease acting alone.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - November 1, 2017 Category: Hematology Authors: P. Corraini, S. K. Sz épligeti, Victor W. Henderson, Anne G. Ording, Erzsébet Horváth‐Puhó, Henrik T. Sørensen Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Risk of stroke in patients with newly diagnosed multiple myeloma: a retrospective cohort study
This study includes consecutive patients 20 years and older who were newly diagnosed with symptomatic multiple myeloma at Taipei Veterans General Hospital, a tertiary medical center, between January 1, 2002 and December 31, 2014. The primary outcome was stroke development. Patients with head injuries, brain tumors, brain parenchymal invasions, or antecedent malignancies were excluded. Hazard ratios (HRs) of stroke risk factors for multiple myeloma patients were estimated by Cox proportional regression analysis. Overall, 395 patients with a median age of 70 years were investigated. In the median follow‐up period of 18 ...
Source: Hematological Oncology - August 21, 2016 Category: Hematology Authors: Gin ‐Yi Lee, Yu‐Ting Lee, Chiu‐Mei Yeh, Pei Hsu, Ting‐Wei Lin, Jyh‐Pyng Gau, Yuan‐Bin Yu, Liang‐Tsai Hsiao, Cheng‐Hwai Tzeng, Tzeon‐Jye Chiou, Jin‐Hwang Liu, Yao‐Chung Liu, Chia‐Jen Liu Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Elevated levels of D-dimers increase the risk of ischaemic and haemorrhagic stroke. Findings from the EPICOR Study.
In conclusion, our data provide clear evidence that elevated levels of D-dimers are potential risk factors not only for ischaemic but also for haemorrhagic strokes. PMID: 25030937 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 17, 2014 Category: Hematology Authors: Di Castelnuovo A, Agnoli C, de Curtis A, Giurdanella MC, Sieri S, Mattiello A, Matullo G, Panico S, Sacerdote C, Tumino R, Vineis P, de Gaetano G, Donati MB, Iacoviello L Tags: Thromb Haemost Source Type: research

Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis
ConclusionsIn comparison to VKA, DOACs were associated with a significant reduction of the rates of thromboembolic events and major bleeding complications in patients with AF and cancer. Further studies are needed to confirm our results.
Source: Journal of Thrombosis and Thrombolysis - October 12, 2020 Category: Hematology Source Type: research

Causes of Death in Patients with Venous Thromboembolism Anticoagulated with Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis
Semin Thromb Hemost DOI: 10.1055/s-0038-1642644Death is more frequent than nonfatal recurrent venous thromboembolism (VTE) and major bleeding after acute VTE. The analysis of the causes of death is fundamental to explore new strategies to reduce mortality rates in these patients. The authors performed a meta-analysis to analyze mortality and independently adjudicated causes of death in anticoagulated patients due to VTE, and to evaluate potential differences between different anticoagulant schemes. They searched MEDLINE and CENTRAL, from January 1, 2000, to January 31, 2017, and performed additional searches in Web sites o...
Source: Seminars in Thrombosis and Hemostasis - May 3, 2018 Category: Hematology Authors: G ómez-Outes, Antonio Terleira-Fern ández, Ana Isabel Lecumberri, Ram ón Su árez-Gea, Mª Luisa Calvo-Rojas, Gonzalo Vargas-Castrill ón, Emilio Tags: Review Article Source Type: research

Management of Cerebral Vein Thrombosis in a Canadian Tertiary Hospital
Introduction: Cerebral vein thrombosis (CVT) is an uncommon cause of stroke and is more likely to affect young adults and children. Women have a three-fold increased risk compared to men, owing to gender specific factors such as oral contraceptive use (OCP), pregnancy, and hormone replacement therapies. The presenting symptoms of CVT are non-specific and include headache, seizure, focal neurological deficits, or coma as the most severe presentation. The rarity and variable symptoms of the disease leads to delayed diagnosis and implementation of treatment. With improved imaging techniques and increased awareness in recent y...
Source: Blood - November 21, 2018 Category: Hematology Authors: Castellucci, L. A., Chiang, P. Tags: 332. Antithrombotic Therapy: Poster II Source Type: research

Novel Bleeding Risk Score for Patients with Atrial Fibrillation on Oral Anticoagulants, including Direct Oral Anticoagulants.
CONCLUSION: In this prospective cohort study of AF patients and predominantly DOAC users, we successfully derived a bleeding risk prediction model with good calibration and discrimination. PMID: 33501722 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 27, 2021 Category: Hematology Authors: Adam L, Feller M, Syrogiannouli L, Del-Giovane C, Donzé J, Baumgartner C, Segna D, Floriani C, Roten L, Fischer U, Aeschbacher S, Moschovitis G, Schläpfer J, Shah D, Amman P, Kobza R, Schwenkglenks M, Kühne M, Bonati L, Beer J, Osswald S, Conen D, Auje Tags: J Thromb Haemost Source Type: research

Safety of apixaban for venous thromboembolic primary prophylaxis in patients with newly diagnosed malignant glioma
In this study, we treated ten patients with newly diagnosed MG with apixaban, 2.5  mg twice daily beginning 2–21 days after craniotomy and continuing for up to 6 months. Unacceptable toxicity was defined by ≥ grade 2 CNS or non-CNS hemorrhage, a thromboembolic event (i.e. stroke) or cardiovascular event requiring anticoagulation or anti-platelet therapy. There were no unacc eptable toxicities to report and no treatment-related adverse events. None of the patients on the study were diagnosed with a VTE while receiving apixaban. We conclude that apixaban can be given safely to patients with primary MG shortly after cra...
Source: Journal of Thrombosis and Thrombolysis - August 4, 2021 Category: Hematology Source Type: research